ArticleClinical ophthalmology (Auckland, N.Z.)2012
Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Managing Bilateral Vernal Keratoconjunctivitis, Keratoconus, and Steroid-Induced Glaucoma: A Threefold Struggle.Cureus · 2025Article
- Role of Serine Protease Inhibitors A1 and A3 in Ocular Pathologies.Investigative ophthalmology & visual science · 2024Review
- Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists.Indian journal of ophthalmology · 2023Article
- The short-term effects of intranasal steroids on intraocular pressure in pediatric population.International ophthalmology · 2022Article
- Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial.Journal of clinical medicine · 2022Article
- Long-term outcomes and risk factors for failure of glaucoma filtering surgery in eyes with vernal keratoconjunctivitis and steroid-induced glaucoma.Indian journal of ophthalmology · 2022Article
- Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients.BMC ophthalmology · 2021Article
- Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseases.Japanese journal of ophthalmology · 2020Article
- Local delivery of corticosteroids in clinical ophthalmology: A review.Clinical & experimental ophthalmology · 2020Review
- Pattern of steroid misuse in vernal keratoconjunctivitis resulting in steroid induced glaucoma and visual disability in Indian rural population: An important public health problem in pediatric age group.Indian journal of ophthalmology · 2019Article
- Case series of children with steroid-Induced glaucoma.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2018Article
- An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Paediatric drugs · 2016Review
- Optical coherence tomography angiography in dural carotid-cavernous sinus fistula.BMC ophthalmology · 2016Article
- Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement.The British journal of ophthalmology · 2014Observational
- Management of vernal keratoconjunctivitis.Ophthalmology and therapy · 2013Article
- Vernal Keratoconjunctivitis: A Case of Anti-IgE Treatment with Short-Lasting Remission.Case reports in ophthalmologyArticle
- Steroid-induced Glaucoma: An Avoidable Irreversible Blindness.Journal of current glaucoma practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe describe clinical characteristics and risk factors for corticosteroid response in children with severe vernal keratoconjunctivitis (VKC).
designRetrospective, noncontrolled, comparative case series.
participantsPatients from three tertiary centers in Singapore.
methodsWe reviewed patients with severe VKC (clinical grade > 2) who were on topical steroid therapy, with a minimum follow-up period of 1 year post-presentation. Logistic regression was used to determine risk factors for corticosteroid response.
main outcome measureCorticosteroid response was defined as intraocular pressure (IOP) >21 mmHg (three consecutive readings), or a rise of more than 16 mmHg from baseline, after commencement of steroid therapy in the absence of other possible causes of raised IOP.
resultsForty-one of 145 (28.3%) patients developed a corticosteroid response, of which eight (5.5%) progressed to glaucoma. The overall mean age of onset of VKC was 9.9 ± 4.4 years. Longer duration of corticosteroid use (OR, 5.06; 95% CI: 1.04-25.56; P = 0.45) and topical dexamethasone 0.01% (OR, 2.25; 95% CI: 1.99-5.08; P = 0.40) were associated with corticosteroid response. Mixed type of VKC (OR, 9.76; 95% CI: 3.55-26.77; P < 0.001), the presence of limbal neovascularization of ≥ three quadrants (OR, 6.33; 95% CI: 2.36-16.97; P < 0.001), and corneal involvement (OR, 3.51; 95% CI: 1.31-9.41; P = 0.012) were significant clinical risk factors after adjusting for potential confounders such as age, sex, ethnicity, duration, and type of corticosteroid used.
conclusionChildren on long-term oral corticosteroids with severe, mixed-type VKC and corneal involvement are more likely to develop corticosteroid response, and may require early treatment to prevent progression to glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.